Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Not Applicable

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: Radiotherapy
Drug: Durvalumab

First Posted Date: 2021-04-20

Last Posted Date: 2021-06-22

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 33

Registration Number: NCT04851132

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study

Conditions: Advanced Colorectal Cancer

First Posted Date: 2021-04-08

Last Posted Date: 2022-03-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 650

Registration Number: NCT04835324

Locations: 🇨🇳
Cancer Hospital,Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing, China

Sequence of Radiation and Targeted Therapy in Brain Metastases

Completed

Conditions: The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases

First Posted Date: 2021-04-06

Last Posted Date: 2021-04-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 570

Registration Number: NCT04832672

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Phase 3

Recruiting

Conditions: Chemotherapy Effect
Esophagus Cancer
Esophagogastric Junction Cancer
Chemoradiation
Targeted Therapy
Immunotherapy

Interventions: Radiation: Radiotherapy
Drug: Platinum based chemotherapy
Drug: Paclitaxel based chemotherapy
Drug: 5-FU Analog based chemotherapy
Drug: Immunotherapy
Drug: Nimotuzumab

First Posted Date: 2021-03-30

Last Posted Date: 2024-12-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 2000

Registration Number: NCT04821778

Locations: 🇨🇳
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

and more 2 locations

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Phase 2

Conditions: Immunotherapy
Esophagus Cancer
Chemoradiotherapy
Oligometastatic Disease

Interventions: Drug: PD-1 antibody
Radiation: Chemoradiation
Drug: Albumin-Bound Paclitaxel
Drug: Cisplatin

First Posted Date: 2021-03-30

Last Posted Date: 2021-03-30

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 35

Registration Number: NCT04821765

Locations: 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Phase 3

Conditions: Non-small Cell Lung Carcinoma

Interventions: Drug: Almonertinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2021-02-21

Last Posted Date: 2022-02-24

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 606

Registration Number: NCT04762459

Locations: 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, China

and more 31 locations

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Phase 2

Recruiting

Conditions: Locally Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Camrelizumab, PD-1 monoclonal antibody
Drug: Apatinib, VEGFR2 antibody

First Posted Date: 2021-02-11

Last Posted Date: 2022-08-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 42

Registration Number: NCT04749394

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

A Real-world Clinical Study of Kapok Initiative

Not Applicable

Suspended

Conditions: Quality of Life

Interventions: Behavioral: Kapok Initiative

First Posted Date: 2021-02-03

Last Posted Date: 2021-02-03

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT04735991

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Phase 2

Conditions: Small-cell Lung Cancer

Interventions: Drug: camrelizumab
Drug: Apatinib Mesylate
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2020-12-24

Last Posted Date: 2020-12-24

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 69

Registration Number: NCT04683198

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

Phase 2

Conditions: Lung Cancer

Interventions: Drug: Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets

First Posted Date: 2020-12-17

Last Posted Date: 2020-12-17

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT04671303

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy